Health Minister Hsueh Jui-yuan (薛瑞元) said Wednesday the ministry's commissioning of Choice Pharma Taiwan to conduct Phase 2 clinical trials of the locally manufactured Medigen COVID-19 vaccine predated a merger between Choice Pharma's parent company and a Shanghai-based firm, amid controversy over possible Chinese involvement in the trials.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Taiwan could mandate traceable washed eggs for national food chains
12/21/2024 10:03 PM - Society
TR could penalize man for trespassing on railway tracks
12/21/2024 09:24 PM - Society
5 injured in collision between Taichung bus and car
12/21/2024 08:21 PM - Science & Tech
Taiwan plans to set up drone testing facility in Chiayi
12/21/2024 06:25 PM - Cross-Strait
Experts sound alarm over low awareness of China threat among Taiwan's youth
12/21/2024 06:08 PM